London, UK, 08 September 2016: Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, is pleased to announce that it received the ‘AIM listing of the Year Award 2016’ at the Biotech and Money Assembly and Awards.
Carl Sterritt, Founder and Chief Executive Officer, commented: “We are delighted to have won the award for ‘AIM listing of the Year’, especially among a group of worthy peers. This award recognises the hard work and vision of the Shield Therapeutics team and the strong support of our shareholders, which together have made this year a successful and dynamic one.”
For further information please contact:
Shield Therapeutics plc +44 (0)191 511 8507
Carl Sterritt, Chief Executive Officer
Richard Jones, Chief Financial Officer
Liberum Capital Limited
+44 (0)20 3100 2222
Financial PR Advisor
Consilium Strategic Communications +44 (0)203 709 5700
About Shield Therapeutics plc
Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. The Company has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA). In addition, the Company is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE’s AIM under the ticker STX. For more information please visit www.shieldtherapeutics.com.
To download this release in pdf format please click here.Back to news